KITE PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California, United States
🇺🇸Baptist Cancer Center, Memphis, Tennessee, United States
🇦🇺Epworth HealthCare, Richmond, Victoria, Australia
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 21
- Registration Number
- NCT06253663
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵Hokkaido University Hospital, Hokkaido, Japan
🇯🇵Tohoku University Hospital, Miyagi, Japan
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 39
- Registration Number
- NCT06079164
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Conditions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776160
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776134
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 300
- Registration Number
- NCT05605899
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 19
- Registration Number
- NCT05537766
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Georgetown University Medical Centre, Washington, District of Columbia, United States
🇮🇹IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 30
- Registration Number
- NCT05459571
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 110
- Registration Number
- NCT05396885
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Northside Hospital, Inc, Atlanta, Georgia, United States
🇺🇸John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, New Jersey, United States
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 230
- Registration Number
- NCT05371093
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇺🇸UC Irvine Health, Orange, California, United States